外路MicroShunt与传统小梁切除术治疗原发性开角型青光眼:随机多中心研究两年结果
这项前瞻性随机多中心试验比较了MicroShunt与小梁切除术治疗原发性开角型青光眼的效果与安全性。2年时,MicroShunt组手术成功率低于小梁切除术组(50.6% vs 64.4%,P=0.005),两组眼压和用药均较基线显著下降,小梁切除术组眼压更低,但低眼压发生率更高(51.1% vs 30.9%,P<0.001)。
要点
- 2年手术成功率MicroShunt组50.6%,低于小梁切除术组的64.4%(P=0.005)。
- 两组平均日间眼压和用药数均较基线显著下降,小梁切除术组眼压降至更低水平。
- 低眼压在小梁切除术组更常见(51.1% vs 30.9%,P<0.001),MicroShunt组6.8%需复位或取出植入物。
核心结论
- 2年时MicroShunt和小梁切除术均显著降低眼压和用药,小梁切除术手术成功率更高。
研究设计与样本
- 前瞻性、随机、多中心试验,在美国和欧洲进行。
- 纳入40-85岁原发性开角型青光眼患者,最大耐受药物治疗下眼压≥15 mmHg且≤40 mmHg。
- 患者按3:1随机分配至MicroShunt植入组(n=395)或小梁切除术组(n=132),均使用0.2 mg/ml丝裂霉素C处理2分钟。
主要发现
- 2年手术成功率MicroShunt组50.6% vs 小梁切除术组64.4%(P=0.005)。
- MicroShunt组平均日间眼压从基线21.1±4.9 mmHg降至24个月13.9±3.9 mmHg,小梁切除术组从21.1±5.0 mmHg降至10.7±3.7 mmHg(两组与基线比较P<0.001)。
- MicroShunt组平均用药从3.1降至0.9,小梁切除术组从2.9降至0.4(两组与基线比较P<0.001)。
- 2年不良事件两组总体相似,但低眼压在小梁切除术组更常见(51.1% vs 30.9%,P<0.001)。
- MicroShunt组6.8%患者发生植入物复位或取出,其中多数在后续青光眼手术时取出装置;两组威胁视力的并发症均不常见。
关键数值与推荐
- 主要有效性终点为手术成功,定义为平均日间眼压较基线降低≥20%且青光眼用药不增加。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare the effectiveness and safety of the MicroShunt (Santen Inc) versus trabeculectomy in patients with primary open-angle glaucoma (POAG). DESIGN: Prospective, randomized, multicenter trial conducted in the United States and Europe. PARTICIPANTS: Adult patients (aged 40-85 years) with mild to severe POAG inadequately controlled on maximum tolerated medical therapy and intraocular pressure (IOP) ≥ 15 mmHg and ≤ 40 mmHg. METHODS: Patients were randomized 3:1 to stand-alone MicroShunt implantation (n = 395) or trabeculectomy (n = 132), both augmented with mitomycin C (MMC) 0.2 mg/ml for 2 minutes. MAIN OUTCOME MEASURES: The primary effectiveness end point was surgical success, defined as ≥ 20% reduction in mean diurnal IOP from baseline with no increase in glaucoma medications. Secondary end points included changes in mean IOP and medication use from baseline and the need for postoperative interventions. RESULTS: At 2 years, the rate of surgical success was lower in the MicroShunt group than in the trabeculectomy group (50.6% vs. 64.4%, P = 0.005). Mean diurnal IOP was reduced from 21.1 ± 4.9 mmHg at baseline to 13.9 ± 3.9 mmHg at 24 months in the MicroShunt group and from 21.1 ± 5.0 mmHg at baseline to 10.7 ± 3.7 mmHg at 24 months in the trabeculectomy group (P < 0.001 compared with baseline in both groups). Mean medication use decreased from 3.1 to 0.9 in the MicroShunt group and from 2.9 to 0.4 in the trabeculectomy group (P < 0.001 compared with baseline in both groups). Adverse events at 2 years were generally similar in the 2 groups, except that hypotony was more common in eyes undergoing trabeculectomy (51.1% vs. 30.9%, P < 0.001). Repositioning or explantation of the implant occurred in 6.8% of MicroShunt patients. The majority of these patients had device removal at the time of subsequent glaucoma surgery. Vision-threatening complications were uncommon in both groups. CONCLUSION: At 2 years, both the MicroShunt and trabeculectomy provided significant reductions in IOP and medication use, with trabeculectomy continuing to have greater surgical success. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
引用
- Panarelli JF, Moster MR, Garcia-Feijoo J, et al. Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: Two-Year Results from a Randomized, Multicenter Study. Ophthalmology. 2023. PMID: 37769852. doi:10.1016/j.ophtha.2023.09.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。